Uses of Brukinsa

Brukinsa has the active ingredient zanubrutinib and is used to treat Nerve Cell Lymphoma. The drug is manufactured by BeiGene Company - China and is used according to a doctor's prescription.

Kinase is an enzyme that promotes cell growth, in our body there are many different types of kinases that help control different stages of development. By blocking a specific enzyme from working, Brukinsa reduces the growth of cancer cells. Brukinsa drug with active ingredient is Zanubrutinib 80mg indicated in the treatment of Neuroblastoma..

Brukinsa tablets are prepared in the form of capsules, for oral use, patients should swallow Brukinsa tablets whole with a glass of water. Brukinsa capsules must not be broken, opened, or chewed. Brukinsa can be taken with or without food. If you miss your dose of Brukinsa, take your next dose as soon as you remember and then return to your normal schedule the next day. It is important to ensure that the patient is taking the correct amount of Brukinsa each time.
Brukinsa blood concentration can be affected by some foods and drugs, so it is necessary to avoid concomitant use of Brukinsa with: Itraconazole, Voriconazole, Posaconazole, Fluconazole, Isavuconazole, Clarithromycin, Diltiazem, Erythromycin, Rifampin and Omeprazole....

Brukinsa can also cause hepatitis B reactivation in patients who have had previous hepatitis. Make sure the doctor knows about the patient's previous diagnosis and treatment of hepatitis B. Patients can also be given medication to prevent herpes simplex virus and jiroveci pneumonia. Use caution when administering Brukinsa to children, pregnant and lactating women; Patients, whether male or female, need to use contraception during the use of Brukinsa; It is necessary to monitor blood counts, watch for serious side effects, cardiac arrhythmias It is necessary to use sun protection measures to avoid skin cancer during the period of taking Brukinsa. Dosage of Brukinsa should be reduced in patients with severe hepatic impairment.

Store Brukinsa in the original, labeled packaging, store at room temperature and in a dry place, do not store in the medicine box, keep Capmatinib out of the reach of children and pets.
If caregivers prepare a dose of Brukinsa for a patient, they should consider wearing gloves or pouring the medication directly from the container into the lid, small cup, or directly into the patient's hand, avoiding touching the tablet. Always wash your hands before and after administering Brukinsa to a patient. Pregnant or nursing women should not prepare doses of Brukinsa for patients. Do not flush Brukinsa down the toilet or throw it in the trash.

Patients can apply a number of different measures to control the side effects of Brukinsa, these measures will be guided and selected by the doctor for each specific patient. The following are some of the most common or important side effects of Brukinsa:
5.1. Leukopenia, increased risk of infection White blood cells play a role in fighting infectious agents for the body. During treatment with Brukinsa, white blood cell counts may decrease and lead to an increased risk of infections. It is important that patients taking Brukinsa tell their doctor or nurse immediately if they have signs of an infection such as: fever over 38 degrees, sore throat, cold, trouble breathing, cough, painful urination or other symptoms. slow-healing ulcers.
Some doctor's recommendations to limit infection while taking Brukinsa :
Wash your hands often; Limit going to crowded places or contact with people showing signs of infection (people showing signs of cold, fever, cough or living with someone with these symptoms); Do not dispose of pet waste while being treated with Brukinsa ; Keep skin wounds or scratches clean at all times; Bathing, personal hygiene, regular dental care; Do not remove corners or trim ingrown fingernails/toenails; Talk to your oncologist before having a dental procedure while taking Brukinsa ; Consult your doctor before receiving any vaccine while taking Brukinsa . 5.2. Decreased Platelet Count Platelets are part of the blood clotting process, so a low platelet count leads to a higher risk of bleeding. If you are taking Brukinsa, tell your doctor if you have any unusual bruising or bleeding (bleeding from the nose or teeth, bloody urine, etc.). Platelet transfusion is necessary if the patient's platelet count is too low while taking Brukinsa.
Besides, patients should also avoid some activities that can cause bleeding during treatment with Brukinsa as follows:
Using razors; Playing contact sports that have the potential to cause injury or bleeding; Concomitant use of Brukinsa with Aspirin or non-steroidal anti-inflammatory drugs (NSAIDs); Use dental floss, toothpicks; Do not brush your teeth with a toothbrush that is too stiff. In rare cases, Brukinsa can cause serious bleeding also known as hemorrhagic diathesis. Patients should contact their doctor immediately if they have any of the stated signs of bleeding or any headaches that do not go away. If you are scheduled to have surgery, you will likely have to stop taking Brukinsa for a period of time, your doctor will let you know when to stop and when to continue.
5.3. Anemia due to reduced red blood cells Red blood cells are responsible for transporting oxygen in the blood to supply tissues in the body, so a low number of these cells will cause the organs in the body to be deprived of oxygen to function. symptoms such as fatigue or lack of energy. Patients should inform their doctor if they have symptoms of anemia such as shortness of breath, fatigue or chest pain ... during treatment with Brukinsa. In some cases, the red blood cell count is so low due to Brukinsa that a blood transfusion may be necessary.
5.4. Rash Some patients may develop a rash while using Brukinsa, which can be corrected by using an alcohol-free moisturizer on the skin and lips, and avoiding moisturizers with fragrances or fragrances. The doctor or nurse may recommend a topical medication if the patient complains of bothersome itching caused by Brukinsa. If the patient's skin cracks or bleeds, be sure to keep the area clean to avoid infection and to inform the doctor of any rash that develops on the skin during treatment with Brukinsa.
5.5. Diarrhea Patients should inform their physician if diarrhea begins so that appropriate interventions can be found, the oncologist can refer the patient to medications to relieve the diarrhea caused by Brukinsa. In addition, patients can apply some measures to reduce diarrhea such as limiting foods high in fiber, avoiding fresh fruits or vegetables, whole grain breads, nuts and cereals. Soluble fiber can absorb liquid and help relieve diarrhea caused by Brukinsa effectively, they are abundant in apple sauce, ripe bananas, canned fruit, oranges, boiled potatoes, white rice, french fries.. Besides, Brukinsa users should pay attention to drink enough water, limit alcohol or caffeine to prevent dehydration due to diarrhea.
5.6. Important but less common side effects of Brukinsa Heart problems: Brukinsa may cause a fast or irregular heartbeat, atrial fibrillation, or atrial flutter. Notify the doctor immediately if the patient feels an irregular heartbeat or if he or she feels that his or her heart is beating fast or irregularly, dizziness, fainting, shortness of breath, or chest tightness. Muscle or joint pain: The doctor or nurse may recommend medication to relieve the pain. Secondary cancer: Secondary cancer is cancer that develops as a result of cancer treatment for another cancer. This is quite rare, but is quite possible years after treatment with Brukinsa, associated with repeated treatment or high doses. A complete blood count should be checked. There is very little risk of developing non-melanoma skin cancer with Brukinsa treatment after many years of treatment. Brukinsa has been linked to the development of skin cancer, so patients should avoid the sun between 10 and 2 p.m., and apply sunscreen (at least SPF 15) daily. wearing sunglasses...

Exposure to Brukinsa to the fetus can lead to birth defects, so patients should not become pregnant or father a child during cancer treatment with Brukinsa. The use of effective contraception or birth control is essential, especially during treatment and for at least 1 week after the end of Brukinsa therapy. Even if the menstrual cycle stops or the patient believes that he or she is not producing sperm, conception is still possible. Note that the patient should not breast-feed while taking Brukinsa and for at least 1 week after the end of treatment. Brukinsa has the active ingredient zanubrutinib and is used to treat neuroblastoma. The drug is manufactured by BeiGene Company - China and is used according to a doctor's prescription.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Reference source: oncolink.org